The Effects & Safety of 5% Lifitegrast Ophthalmic Solution in Subjects

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05969743` - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease	Phase 2
Active, not recruiting	`NCT04669210` - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT	Phase 2
Completed	`NCT04014790` - RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Recruiting	`NCT06008808` - Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT03395860` - Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT	Phase 2
Completed	`NCT03207958` - Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation	Phase 1
Completed	`NCT03414645` - Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease	Phase 1/Phase 2
Completed	`NCT03846479` - Itacitinib for Low Risk GVHD	Phase 2
Active, not recruiting	`NCT01927120` - In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis	Phase 2
Recruiting	`NCT06321003` - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting	`NCT06279585` - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD	N/A
Suspended	`NCT05617625` - CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome	Phase 2
Not yet recruiting	`NCT06392711` - Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia	Phase 1
Withdrawn	`NCT00723593` - Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease	N/A
Recruiting	`NCT03148197` - Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)	N/A
Recruiting	`NCT03456817` - HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis	Phase 2
Completed	`NCT00827398` - Treatment of Steroid Resistant GVHD by Infusion MSC	Phase 1/Phase 2
Recruiting	`NCT03842696` - Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 1/Phase 2
Completed	`NCT03605927` - CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease	Phase 1
Recruiting	`NCT04688021` - A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.	Phase 2

NCT number	NCT04792580
Study type	Interventional
Source	Yee, Richard W., M.D.
Contact	Richard W Yee, MD
Phone	7133063051
Email	drrichardyee@gmail.com
Status	Recruiting
Phase	Early Phase 1
Start date	October 22, 2022
Completion date	October 30, 2023

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms